Financing follows peer-reviewed NeuroPulse pilot study results and supports a pivotal trial of Rhyvive™, an …
PR Newswire
© Israel Daily | All Rights Reserved
Latest in PR Newswire
-
-
PR Newswire
Jiahui Launches International Cell Therapy Center to Expand Global Access to CAR-T Treatment
SHANGHAI, Oct. 28, 2026 /PRNewswire/ — Jiahui International Hospital launched Jiahui International Cell Therapy Center, …
-
PR Newswire
A2 GLOBAL ELECTRONICS ACHIEVES AS9100 CERTIFICATION, STRENGTHENING QUALITY CONTROLS FOR VALUE-ADDED COMPONENT SERVICES
ST. PETERSBURG, Fla., Oct. 27, 2026 /PRNewswire/ — A2 Global Electronics + Solutions, a global …
-
PR Newswire
XCMG Advances Belt and Road Talent Cooperation with Launch of Joint Education Programs for Students from Uzbekistan and Indonesia
XUZHOU, China, Oct. 27, 2026 /PRNewswire/ — XCMG Group recently held opening ceremonies in Xuzhou for …
-
PR Newswire
Getac’s Next Generation B360X and B360X Pro Fully Rugged Notebooks Bring Powerful Edge AI Performance to Frontline Professionals
Latest additions to Getac’s flagship B360 lineup boast advanced Intel® CoreTM Ultra Series 3 processors …
-
PR Newswire
Genesis Momentum Powers Cellebrite’s Autumn Release: More Evidence, Deeper Insight, Broader Access for Investigations
Investigators report dramatic gains in what they uncover using Agentic AI vs. manual review; the …
-
TYSONS CORNER, VA and PETAH TIKVA, ISRAEL, Oct. 20, 2026 /PRNewswire/ — Cellebrite DI Ltd. …
-
PR Newswire
Segway Powersports Highlights Off-Road Performance and Smart Technology at 140th Canton Fair
GUANGZHOU, China, Oct. 20, 2026 /PRNewswire/ — Segway Powersports, a global innovator in intelligent off-road …
-
PR Newswire
Continuity Biosciences Awarded $9.6 Million Grant to Advance Ultra-Long-Acting Implant for HIV Prevention
Funding supports development of a subcutaneous implant designed to deliver HIV prevention medicine for multiple …
-
PR Newswire
Lutris Pharma Announces Positive Updated Phase 2 Data Demonstrating Durable, Mechanism-Directed Benefit of LUT014 Gel for EGFRI-Induced Acneiform Rash at the EADV Congress
LUT014 0.1% Gel Demonstrated Statistically Significant Improvement in Treatment Success Achieved by 71.8% of Patients …
Newer Posts